BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Holdings Lifted by Barclays PLC

Barclays PLC increased its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 31.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 545,008 shares of the company's stock after purchasing an additional 131,743 shares during the period. Barclays PLC owned 0.29% of BridgeBio Pharma worth $13,876,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Bfsg LLC raised its stake in BridgeBio Pharma by 175.6% during the second quarter. Bfsg LLC now owns 1,240 shares of the company's stock worth $31,000 after purchasing an additional 790 shares during the period. Headlands Technologies LLC acquired a new stake in shares of BridgeBio Pharma during the 2nd quarter worth $48,000. Values First Advisors Inc. purchased a new position in shares of BridgeBio Pharma in the 3rd quarter worth $57,000. CWM LLC boosted its holdings in BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company's stock valued at $88,000 after acquiring an additional 1,964 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its position in BridgeBio Pharma by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock valued at $117,000 after acquiring an additional 1,645 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO traded up $0.22 during midday trading on Monday, reaching $27.71. 1,869,131 shares of the company's stock were exchanged, compared to its average volume of 1,909,260. The stock has a market capitalization of $5.24 billion, a PE ratio of -11.50 and a beta of 1.08. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $44.32. The business's fifty day moving average price is $25.64 and its two-hundred day moving average price is $26.09.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Oppenheimer began coverage on BridgeBio Pharma in a report on Thursday, October 3rd. They issued a "market perform" rating on the stock. Piper Sandler began coverage on shares of BridgeBio Pharma in a report on Wednesday, September 4th. They issued an "overweight" rating and a $46.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $70.00 price objective on shares of BridgeBio Pharma in a research note on Monday, September 16th. HC Wainwright reissued a "buy" rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research report on Monday. Finally, Bank of America lifted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has an average rating of "Moderate Buy" and a consensus target price of $47.69.

Insider Buying and Selling at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $93,135.96. Following the transaction, the chief financial officer now owns 93,758 shares of the company's stock, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Neil Kumar sold 27,389 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the completion of the sale, the chief executive officer now directly owns 4,897,443 shares of the company's stock, valued at approximately $109,751,697.63. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.66% of the stock is owned by insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.